Antiangiogenic therapy for breast cancer

Breast Cancer Research

Table 4 Trials of bevacizumab in early-stage breast cancer: adjuvant therapy

Reference	Phase	Number of patients	Treatment	Clinical CHF	LVEF <40%	DFS
Miller et al. [40]	II (two-arm non-randomised)	104	B¹ + (ddAC → paclitaxel)	2	4	NR
		122 (HER2 status not reported)	ddAC → B + paclitaxel	2	1	NR
Hart et al. [41]	IIb (randomised)	59	HER2-negative randomised: B² + AC → T	1	NR	NR
		61	B² + ACT	2	NR	NR
		39	HER2-positive: B² + TCH	0	NR	NR
Mayer et al. [42]	II	40	B² +/- trastuzumab +/- endocrine therapy	0	0	NR
McArthur et al. [112]	II	76	B² + ddAC × 4 → nab-paclitaxel × 4	0	0	NR

AC, doxorubicin + cyclophosphamide; ACT, doxorubicin + cyclophosphamide + docetaxel; B¹, bevacizumab 10 mg/kg every second weeks × 26; B², bevacizumab15 mg/kg every 3 weeks for a total of 52 weeks; CHF, congestive heart failure; ddAC, dose dense doxorubicin + cyclophosphamide; DFS, diseas-free survival; LVEF, left vntricular ejection fraction; NR, not reported; T, docetaxel; TCH, docetaxel + carboplatin + trastuzumab.

ISSN: 1465-542X